MEDARTIS HOLDING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.65 CHF | -0.81% |
|
-1.00% | -5.48% |
| Apr. 04 | Global markets live: Novo Nordisk, Ocado, Walt Disney, Apple, Tesla... |  |
| Apr. 04 | Medartis Issues CFH116 Million Convertible Bonds | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 60% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 114.28 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.56 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -5.48% | 1.2B | B- | ||
| +8.70% | 124B | A- | ||
| +6.05% | 9.31B | C | ||
| +23.36% | 7.6B | C | ||
| +32.10% | 5.29B | B+ | ||
| +8.61% | 3.45B | C- | ||
| -9.10% | 2.79B | B- | ||
| -2.71% | 2.3B | - | - | |
| -0.20% | 2.23B | - | ||
| -20.42% | 1.86B | - | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MED Stock
- Ratings Medartis Holding AG